Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

Systematic review comparing meropenem with imipenem plus cilastatin in the treatment of severe infections.

OBJECTIVE: To compare the effectiveness of meropenem with imipenem plus cilastatin in the treatment of severe infections. DATA SOURCES: CENTRAL, EMBASE and MEDLINE were searched for abstracts and papers. All searching was completed in March 2004. No restriction was placed on language. STUDY SELECTI...

Description complète

Détails bibliographiques
Auteurs principaux:	Edwards, S, Emmas, C, Campbell, H
Format:	Journal article
Langue:	English
Publié:	2005

Documents similaires

Cost-utility analysis comparing meropenem with imipenem plus cilastatin in the treatment of severe infections in intensive care.
par: Edwards, S, et autres
Publié: (2006)

Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients
par: Xi You, et autres
Publié: (2024-03-01)

Imipenem/Cilastatin/Relebactam for Complicated Infections: A Real-World Evidence
par: Pasquale Sansone, et autres
Publié: (2024-05-01)

Retrospective evaluation of piperacillin–tazobactam, imipenem–cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia
par: Eman Youssif, et autres
Publié: (2018-07-01)

In vitro study of the embolic characteristics of imipenem/cilastatin particles
par: Hiroki Nakamura, et autres
Publié: (2024-03-01)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
par: Maria Agudelo, et autres
Publié: (2019-01-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
par: Alex A. Erasmo
Publié: (2004-07-01)

Corrigendum to “Therapeutic drug monitoring of imipenem/cilastatin and meropenem in critically ill adult patients” [Journal of Global Antimicrobial Resistance 36 (2024) 252-259]
par: Xi You, et autres
Publié: (2024-03-01)

Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres
par: Ryan K. Shields, et autres
Publié: (2024-06-01)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
par: Takahiro Arima, et autres
Publié: (2022-01-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
par: Mona I. Shaaban, et autres
Publié: (2017-04-01)

First case report of a vertebral osteomyelitis caused by carbapenem-resistant Enterobacter cloacae treated with imipenem/cilastatin/relebactam prolonged infusion then meropenem/vaborbactam in continuous infusion
par: Paul Laffont-Lozes, et autres
Publié: (2024-10-01)

Cost–effectiveness of imipenem/cilastatin/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia
par: Jaesh Naik, et autres
Publié: (2023-01-01)

A Prospective Randomized Trial of Imipenem-Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra-Abdominal and Pelvic Infections
par: Lionel A Mandell, et autres
Publié: (1993-01-01)

Imipenem/cilastatin encapsulation in UIO-66-NH2 carrier as a new strategy for combating imipenem-resistant Pseudomonas aeruginosa isolates
par: Shakila Baei Lashaki, et autres
Publié: (2025-05-01)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
par: Chang-Hua Chen, et autres

Increased antibiofilm and growth inhibitory effect of Imipenem/Cilastatin nanoliposomes against clinical Pseudomonas aeruginosa isolates
par: Faezeh Milani, et autres
Publié: (2023-09-01)

Transcatheter arterial embolization using imipenem/cilastatin sodium and microspheres for traumatic pseudoaneurysm: A case report
par: Takaki Hirano, et autres
Publié: (2022-12-01)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
par: Xiaokui Huo, et autres
Publié: (2019-09-01)

CLINICAL AND PHARMACOECONOMIC ANALYSIS OF CARBAPENEMS (MEROPENEM, IMIPENEM AND DORIPENEM) IN NOSOCOMIAL PNEUMONIA TREATMENT
par: I. I. Shteynberg, et autres
Publié: (2015-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation
par: C Kani, et autres
Publié: (2005-06-01)

Successful treatment of multiple microbleeds in a large area of the small bowel by transcatheter arterial embolization using imipenem/cilastatin as embolization material
par: Sakiko Hiraki, MD, et autres
Publié: (2023-09-01)

Mutations leading to ceftolozane/tazobactam and imipenem/cilastatin/relebactam resistance during in vivo exposure to ceftazidime/avibactam in Pseudomonas aeruginosa
par: Glenn J. Rapsinski, et autres
Publié: (2025-03-01)

Decrease in the effectiveness of valproic acid against the background of antibacterial therapy with imipenem/cilastatin in pediatric practice: A case report
par: A. B. Strok, et autres
Publié: (2024-01-01)

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection
par: A. K. Chaudhary, et autres
Publié: (2010-01-01)

Determination of Antimicrobial Resistance and the Impact of Imipenem + Cilastatin Synergy with Tetracycline in <i>Pseudomonas aeruginosa</i> Isolates from Sepsis
par: Telma de Sousa, et autres
Publié: (2023-11-01)

Transcatheter arterial embolization for acute lower gastrointestinal bleeding using imipenem/cilastatin: a single-center retrospective study
par: Sakiko Hiraki, et autres
Publié: (2023-03-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation
par: Kani C., et autres
Publié: (2005-07-01)

Mutant Prevention Concentrations of Imipenem and Meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii
par: E. Dahdouh, et autres
Publié: (2014-01-01)

Real-world pharmacovigilance investigation of imipenem/cilastatin: signal detection using the FDA Adverse Event Reporting System (FAERS) database
par: Peng Jia, et autres
Publié: (2025-02-01)

Efficacy and safety of novel carbapenem-β-lactamase inhibitor combinations: imipenem-cilastatin/relebactam results from randomized controlled trials
par: Qingxin Yang, et autres
Publié: (2023-12-01)

Imipenem and Meropenem: Comparison of In Vitro Activity, Pharmacokinetics, Clinical Trials and Adverse Effects
par: George G Zhanel, et autres
Publié: (1998-01-01)

Molecular Epidemiology and Mechanisms of High-Level Resistance to Meropenem and Imipenem in Pseudomonas aeruginosa
par: Hassuna NA, et autres
Publié: (2020-01-01)

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China
par: Chen Y, et autres
Publié: (2018-11-01)

In vitro activity of meropenem, imipenem, cefepime, cefoxitin and ciprofloxacin against multiresistant Klebsiella pneumoniae.
par: P Pruekprasert, et autres
Publié: (2006-06-01)

Systematic review and meta-analysis of colistin plus meropenem therapy for the treatment of nosocomial pneumonia
par: Hazhir Moradi, et autres
Publié: (2024-12-01)

A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve.
par: Le Zou, et autres
Publié: (2019-01-01)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
par: Rémy A. Bonnin, et autres
Publié: (2023-01-01)

Review of In Vitro Efficacy of Ceftazidime-Avibactam, Meropenem-Vaborbactam and Imipenem-Relebactam in Carbapenemase Producing Klebsiella pneumoniae Isolates
par: Özlem AYDEMİR, et autres
Publié: (2023-09-01)

Real-world use of imipenem/cilastatin/relebactam for the treatment of KPC-producing Klebsiella pneumoniae complex and difficult-to-treat resistance (DTR) Pseudomonas aeruginosa infections: a single-center preliminary experience
par: Cristiana Leanza, et autres
Publié: (2024-07-01)